TRPC6 channel blocker as potential therapeutics for pulmonal and renal diseases

The invention comprises diterpene derivatives for the treatment of pulmonary hypertension in conjunction with respiratory disorders, especially asthma and COPD. The pharmacological effect is mediated by selective block of TRPC6, a member of the subfamily of canonical transient receptor potential channels.

Further Information: PDF

GWT-TUD GmbH; FB Sächsische PatentVerwertungsAgentur (SPVA)
Phone: +49 351 25933 120

Contact
Beate-Victoria Ermisch

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Bringing bio-inspired robots to life

Nebraska researcher Eric Markvicka gets NSF CAREER Award to pursue manufacture of novel materials for soft robotics and stretchable electronics. Engineers are increasingly eager to develop robots that mimic the…

Bella moths use poison to attract mates

Scientists are closer to finding out how. Pyrrolizidine alkaloids are as bitter and toxic as they are hard to pronounce. They’re produced by several different types of plants and are…

AI tool creates ‘synthetic’ images of cells

…for enhanced microscopy analysis. Observing individual cells through microscopes can reveal a range of important cell biological phenomena that frequently play a role in human diseases, but the process of…

Partners & Sponsors